Navigating the methodological, ethical, and operational challenges of Trials within Cohorts (TwiCs): insights from a...

Trials within Cohorts (TwiCs) provide a pragmatic framework to improve recruitment and external validity by embedding randomized controlled trials within longitudinal observational cohorts. In pediatrics, and particularly in rare diseases, this design is especially attractive but remains difficult to implement in routine practice due to intertwined methodological, ethical, and operational complexities. Building on the development of a national pediatric platform for idiopathic nephrotic syndrome in France, this commentary highlights key challenges and proposes practical strategies to address them.

We focus on three domains: (i) informed consent, with particular attention to the ethical and regulatory challenges raised by staged information and deferred consent approaches; (ii) data quality, including the long-term requirements for high-quality, interoperable, and research-ready clinical data; and (iii) sustainability, covering governance and funding models needed to maintain a cohort-based trial infrastructure beyond short-term, project-driven grants.

We argue that scalable pediatric TwiCs would benefit from secure and family-centered e-consent solutions, robust real-world data infrastructures aligned with interoperability standards, and hybrid funding strategies.

Overall, this commentary offers practical strategies to help teams overcome key ethical, methodological, and operational challenges to implementing pediatric TwiCs.

Trials within Cohorts (TwiCs) represent an innovative approach to clinical research where randomized trials are embedded directly into existing groups of patients, known as cohorts. By using this framework, researchers can ensure that their findings more accurately reflect real-world medical practice. This design is particularly valuable in fields like pediatrics and the study of rare diseases, where the limited number of available patients often makes traditional trial recruitment exceptionally difficult. Despite their potential, implementing TwiCs involves practical complexities that require careful management. One primary challenge involves the information and consent process, as researchers must find ways to properly inform patients and families while complying with strict national ethical and regulatory frameworks. In addition, ensuring the accuracy and seamless sharing of long-term medical data remains a significant technical struggle, as routine clinical data require substantial curation to be "research-ready." There is also the persistent issue of financial sustainability, as traditional funding models often prioritize individual short-term projects rather than the long-term maintenance required to keep a research infrastructure functional over many years. Drawing from experience with a national platform for children with kidney disease in France, several strategic solutions can help overcome these difficulties. Utilizing digital tools such as electronic consent can streamline the enrollment process, improve the delivery of information, and make it more accessible for families to participate. Furthermore, investing in robust and interoperable data systems ensures that high-quality information is consistently available for analysis. Finally, a shift in funding strategy is essential, moving away from temporary grants toward sustained support that recognizes cohorts as vital research infrastructures. By adopting these improvements, TwiCs can become a powerful and efficient tool for evaluating how medical treatments perform in everyday clinical settings.